Zymeworks Inc (ZYME) has issued an announcement.
Zymeworks Inc. has bolstered its board of directors with the strategic appointment of Dr. Neil Gallagher, who will be joining as a Class I director with his term set to expire at the 2025 annual stockholders’ meeting. Dr. Gallagher’s selection was free from any conflicting transactions and he will be fairly compensated through the Company’s standard plan, which includes a significant initial stock option grant. His expertise will also add value to the research and development committee, signifying a commitment to innovation and governance, and potentially sparking the interest of investors monitoring executive moves and company prospects.
Learn more about ZYME stock on TipRanks’ Stock Analysis page.
